These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38925627)

  • 1. Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter Trial.
    Barry A; Helget LN; Androsenko M; Wu H; Kramer B; Newcomb JA; Brophy MT; Davis-Karim A; England BR; Ferguson R; Pillinger MH; Neogi T; Palevsky PM; Merriman TR; O'Dell JR; Mikuls TR
    Arthritis Rheumatol; 2024 Jun; ():. PubMed ID: 38925627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial.
    Timilsina S; Brittan K; O'Dell JR; Brophy M; Davis-Karim A; Henrie AM; Neogi T; Newcomb J; Palevsky PM; Pillinger MH; Pittman D; Taylor TH; Wu H; Mikuls TR
    Contemp Clin Trials; 2018 May; 68():102-108. PubMed ID: 29597007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial.
    Helget LN; Davis-Karim A; O'Dell JR; Mikuls TR; Newcomb JA; Androsenko M; Brophy MT; England BR; Ferguson R; Pillinger MH; Neogi T; Wu H; Palevsky PM
    Am J Kidney Dis; 2024 Jun; ():. PubMed ID: 38906504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis.
    Maher D; Reeve E; Hopkins A; Tan JM; Tantiongco M; Ailabouni N; Woodman R; Stamp L; Bursill D; Proudman S; Wiese M
    Arthritis Care Res (Hoboken); 2024 Jun; 76(6):871-881. PubMed ID: 38303574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
    Jackson RL; Hunt B; MacDonald PA
    BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. African American patients with gout: efficacy and safety of febuxostat vs allopurinol.
    Wells AF; MacDonald PA; Chefo S; Jackson RL
    BMC Musculoskelet Disord; 2012 Feb; 13():15. PubMed ID: 22316106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout.
    Tedeschi SK; Hayashi K; Zhang Y; Choi H; Solomon DH
    Ann Rheum Dis; 2024 May; ():. PubMed ID: 38724073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
    Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
    Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An updated systematic review and meta-analysis of randomised controlled trials on the effects of urate-lowering therapy initiation during a gout flare.
    Tai V; Gow P; Stewart S; Satpanich P; Li C; Abhishek A; Dalbeth N
    Semin Arthritis Rheum; 2024 Apr; 65():152367. PubMed ID: 38215627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allopurinol for chronic gout.
    Seth R; Kydd AS; Buchbinder R; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006077. PubMed ID: 25314636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Gout Flares in People Starting Allopurinol Using the Start-Low Go-Slow Dose Escalation Strategy.
    Stamp LK; Horne A; Mihov B; Drake J; Haslett J; Chapman P; Frampton C; Dalbeth N
    Arthritis Care Res (Hoboken); 2024 May; ():. PubMed ID: 38766703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Quilisadio JEC; Salido EO; Penserga EG
    Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions for tophi in gout.
    Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between the initial dose urate-lowering drugs and gout flares in adult males with gout.
    Li X; Shao Q; Shen J; Ren S; Li L; Lu H; Chen S
    Rheumatology (Oxford); 2024 May; 63(6):1599-1606. PubMed ID: 37610331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.
    van de Laar CJ; Janssen CA; Janssen M; Oude Voshaar MAH; Al MJ; van de Laar MAFJ
    PLoS One; 2022; 17(1):e0261940. PubMed ID: 35089941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout.
    Coleman GB; Dalbeth N; Frampton C; Haslett J; Drake J; Su I; Horne AM; Stamp LK
    J Rheumatol; 2022 Dec; 49(12):1372-1378. PubMed ID: 35777814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gout management: an update].
    Ankli B; Krähenbühl S
    Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.